|
| Publications [#197876] of Daniel B. Mark
Papers Published
- EL Eisenstein, ED Peterson, JG Jollis, BE Tardiff, RM Califf, JD Knight, DB Mark, Assessing the value of newer pharmacologic agents in non-ST elevation patients: a decision support system application.,
Proceedings : a conference of the American Medical Informatics Association / ... AMIA Annual Fall Symposium. AMIA Fall Symposium
(1997),
pp. 273-7, ISSN 1091-8280
(last updated on 2011/11/29)
Abstract:
Newer pharmacologic agents have demonstrated significant clinical and economic benefit in high-risk percutaneous transluminal coronary angioplasty (PTCA) patients. However, the higher costs of these agents may prohibit their use in lower-risk coronary artery disease (CAD) populations. We developed a decision support system (DSS) to determine the level of clinical effectiveness these newer agents must exhibit to be either cost-neutral or cost-effective in non-ST elevation patients. Our DSS evaluated six month cumulative costs, increased years of life saved (YOLS), and lifetime cost-effectiveness. We found that these therapies can cost as much as $1500 and be cost-neutral at six months if they reduce the composite endpoint of death, myocardial infarction (MI), or revascularization by 15%, and they may cost as much as $3000 and be cost-effective if they reduce this endpoint by 10%.
Keywords:
Angioplasty, Balloon, Coronary • Antibodies, Monoclonal • Coronary Disease • Cost-Benefit Analysis • Decision Support Systems, Clinical* • Decision Support Techniques • Drug Therapy, Computer-Assisted* • Electrocardiography • Humans • Immunoglobulin Fab Fragments • Platelet Aggregation Inhibitors • Platelet Glycoprotein GPIIb-IIIa Complex • Quality-Adjusted Life Years • Survival Analysis • Value of Life • antagonists & inhibitors* • economics • economics* • mortality • physiopathology • therapeutic use • therapy*
|
